• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients.活化的调节性T细胞和记忆性T细胞在卵巢癌患者的恶性腹水中积聚。
Cancer Immunol Immunother. 2015 Mar;64(3):337-47. doi: 10.1007/s00262-014-1636-6. Epub 2014 Nov 22.
2
[Detection of lymphocyte subsets in the peripheral blood of patients with malignant ovarian tumors].[恶性卵巢肿瘤患者外周血淋巴细胞亚群的检测]
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014 Jun;30(6):627-9, 634.
3
Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.卵巢癌相关腹水表现出免疫环境改变:对抗肿瘤免疫的影响。
Anticancer Res. 2009 Aug;29(8):2875-84.
4
Association between effector-type regulatory T cells and immune checkpoint expression on CD8 T cells in malignant ascites from epithelial ovarian cancer.上皮性卵巢癌恶性腹水效应型调节性 T 细胞与 CD8 T 细胞免疫检查点表达的相关性。
BMC Cancer. 2022 Apr 21;22(1):437. doi: 10.1186/s12885-022-09534-z.
5
Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.与血液和肿瘤淋巴细胞相比,从卵巢癌患者腹水中分离出的淋巴细胞存在显著差异。CD3+CD56+细胞与铂耐药性的关联。
Gynecol Oncol. 2007 Jul;106(1):75-81. doi: 10.1016/j.ygyno.2007.02.029. Epub 2007 Apr 11.
6
Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.卵巢癌患者的 Th1 免疫受损是由肿瘤微环境中的 TNFR2+Treg 介导的。
Clin Immunol. 2013 Oct;149(1):97-110. doi: 10.1016/j.clim.2013.07.003. Epub 2013 Jul 25.
7
Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses.耗竭调节性 T 淋巴细胞通过增强抗原特异性 T 细胞免疫应答来逆转促肿瘤和抗肿瘤免疫之间的失衡。
PLoS One. 2012;7(10):e47190. doi: 10.1371/journal.pone.0047190. Epub 2012 Oct 17.
8
Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity.卵巢癌患者腹水中的外泌体:来源及其对抗肿瘤免疫的影响。
Oncol Rep. 2011 Mar;25(3):749-62. doi: 10.3892/or.2010.1119. Epub 2010 Dec 22.
9
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.CD8+T 细胞与 CD4+CD25+FOXP3+和 FOXP3-T 细胞的比值与人类浆液性卵巢癌的不良临床结局相关。
PLoS One. 2013 Nov 14;8(11):e80063. doi: 10.1371/journal.pone.0080063. eCollection 2013.
10
Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer.在高级别浆液性卵巢癌中,表达上皮内淋巴细胞标志物 CD103(αE/β7 整合素)的 CD8+ T 细胞显著升高。
Gynecol Oncol. 2010 Sep;118(3):228-36. doi: 10.1016/j.ygyno.2010.05.016. Epub 2010 Jun 11.

引用本文的文献

1
Stemness-driven clusters in ovarian cancer: immune characteristics and prognostic implications.卵巢癌中由干性驱动的簇:免疫特征及预后意义
Front Oncol. 2025 Jun 11;15:1577283. doi: 10.3389/fonc.2025.1577283. eCollection 2025.
2
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements.肿瘤微环境在卵巢癌转移及临床进展中的作用
J Transl Med. 2025 May 14;23(1):539. doi: 10.1186/s12967-025-06508-0.
3
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.用地尼白介素-妥昔单抗(ONTAK)进行腹腔内免疫治疗复发性难治性卵巢癌。
Gynecol Oncol. 2024 Dec;191:74-79. doi: 10.1016/j.ygyno.2024.09.019. Epub 2024 Oct 2.
4
Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.患者来源的无细胞腹水通过激活关键信号通路影响卵巢癌细胞系中的药物反应。
Mol Oncol. 2025 Jan;19(1):81-98. doi: 10.1002/1878-0261.13726. Epub 2024 Sep 8.
5
Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study).PRaG 方案联合腹腔内注射 PD-1 抑制剂治疗晚期难治性伴有癌性腹水的实体瘤的 I/II 期临床研究(PRaG4.0P 研究)。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241264169. doi: 10.1177/15330338241264169.
6
Sindbis Virus Vaccine Platform: A Promising Oncolytic Virus-Mediated Approach for Ovarian Cancer Treatment.辛德毕斯病毒疫苗平台:一种用于卵巢癌治疗的有前景的溶瘤病毒介导方法。
Int J Mol Sci. 2024 Mar 2;25(5):2925. doi: 10.3390/ijms25052925.
7
The complex role of IL-10 in malignant ascites: a review.IL-10 在恶性腹水的复杂作用:综述。
Cancer Immunol Immunother. 2024 Jan 27;73(2):32. doi: 10.1007/s00262-023-03616-y.
8
Cyclooxygenase-2 Blockade Is Crucial to Restore Natural Killer Cell Activity before Anti-CTLA-4 Therapy against High-Grade Serous Ovarian Cancer.在针对高级别浆液性卵巢癌的抗CTLA-4治疗之前,环氧化酶-2阻断对于恢复自然杀伤细胞活性至关重要。
Cancers (Basel). 2023 Dec 22;16(1):80. doi: 10.3390/cancers16010080.
9
Integrative Analysis of Single-Cell and Bulk RNA Sequencing Reveals Prognostic Characteristics of Macrophage Polarization-Related Genes in Lung Adenocarcinoma.单细胞与批量RNA测序的综合分析揭示肺腺癌中巨噬细胞极化相关基因的预后特征
Int J Gen Med. 2023 Nov 3;16:5031-5050. doi: 10.2147/IJGM.S430408. eCollection 2023.
10
Tissue resident memory T cells are enriched and dysfunctional in effusion of patients with malignant tumor.组织驻留记忆性T细胞在恶性肿瘤患者的积液中富集且功能失调。
J Cancer. 2023 May 5;14(7):1223-1231. doi: 10.7150/jca.83615. eCollection 2023.

本文引用的文献

1
CD147 (Basigin/Emmprin) identifies FoxP3+CD45RO+CTLA4+-activated human regulatory T cells.CD147(Basigin/Emmprin)可识别 FoxP3+CD45RO+CTLA4+-活化的人调节性 T 细胞。
Blood. 2011 Nov 10;118(19):5141-51. doi: 10.1182/blood-2011-02-339242. Epub 2011 Sep 21.
2
Epithelial ovarian cancer.上皮性卵巢癌
J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. doi: 10.6004/jnccn.2011.0008.
3
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype.卵巢癌肿瘤浸润调节性 T 细胞(Treg)与转移表型相关。
Gynecol Oncol. 2010 Mar;116(3):556-62. doi: 10.1016/j.ygyno.2009.11.020. Epub 2009 Dec 14.
4
Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro.人上皮性卵巢癌细胞衍生的细胞因子协同诱导活化的CD4⁺CD25⁻CD45RA⁺初始T细胞表达叉头框蛋白3,并在体外表现出抑制能力。
Cancer Sci. 2009 Nov;100(11):2143-51. doi: 10.1111/j.1349-7006.2009.01286.x. Epub 2009 Jul 10.
5
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.上皮内T细胞与肿瘤增殖:对晚期浆液性卵巢癌手术细胞减灭术获益的影响
Cancer. 2009 Jul 1;115(13):2891-902. doi: 10.1002/cncr.24317.
6
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.表达FoxP3转录因子的人CD4+ T细胞的功能划分与分化动力学
Immunity. 2009 Jun 19;30(6):899-911. doi: 10.1016/j.immuni.2009.03.019. Epub 2009 May 21.
7
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.通过CCL22/CCR4募集的调节性T细胞在原发性乳腺肿瘤周围的淋巴浸润中被选择性激活,并导致不良临床结局。
Cancer Res. 2009 Mar 1;69(5):2000-9. doi: 10.1158/0008-5472.CAN-08-2360. Epub 2009 Feb 24.
8
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.肿瘤浸润性T淋巴细胞在晚期卵巢癌原发灶和转移灶中的预后意义
Cancer Immunol Immunother. 2009 Mar;58(3):449-59. doi: 10.1007/s00262-008-0583-5. Epub 2008 Sep 13.
9
Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry.通过流式细胞术同时测量积液中上皮细胞凋亡和细胞表面表型的方法。
Nat Protoc. 2008;3(6):955-64. doi: 10.1038/nprot.2008.77.
10
The impact of T-cell immunity on ovarian cancer outcomes.T细胞免疫对卵巢癌预后的影响。
Immunol Rev. 2008 Apr;222:101-16. doi: 10.1111/j.1600-065X.2008.00614.x.

活化的调节性T细胞和记忆性T细胞在卵巢癌患者的恶性腹水中积聚。

Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients.

作者信息

Landskron Johannes, Helland Øystein, Torgersen Knut Martin, Aandahl Einar Martin, Gjertsen Bjørn Tore, Bjørge Line, Taskén Kjetil

机构信息

Biotechnology Centre of Oslo, University of Oslo, Oslo, Norway.

出版信息

Cancer Immunol Immunother. 2015 Mar;64(3):337-47. doi: 10.1007/s00262-014-1636-6. Epub 2014 Nov 22.

DOI:10.1007/s00262-014-1636-6
PMID:25416072
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11029521/
Abstract

Invasive ovarian cancer is associated with poor outcome. The presence of infiltrating regulatory T-cells (Tregs) suppresses protective anti-tumor immune responses, and their accumulation into the tumor microenvironment correlates with reduced survival in ovarian cancer patients. Here, we conducted a detailed characterization of CD4(+) T-cells, CD8(+) T-cells and Treg subsets in the peripheral blood and malignant ascites fluid from seventeen patients with ovarian carcinoma of epithelial origin. Cell distribution, activation status and proliferation status were assessed by multi-color flow cytometry. In ascites fluid, a significant accumulation of CD8(+) cytotoxic T-cells and Tregs was observed compared to peripheral blood. Furthermore, a skewing toward the CD45RA(-) effector/memory compartment was observed in all T-cell subsets in the ascites fluid, but was most pronounced in the Treg population. Regulatory T-cells in the malignant ascites were more activated and had a higher proliferation rate compared to blood-derived cells from the same patient, and their number in ascites was positively correlated with the number of epithelial cells in effusion. In summary, we demonstrate an accumulation of activated CD4(+), CD8(+) and regulatory T-cells in the cancer microenvironment of ovarian carcinoma.

摘要

侵袭性卵巢癌预后较差。浸润性调节性T细胞(Tregs)的存在会抑制保护性抗肿瘤免疫反应,它们在肿瘤微环境中的积累与卵巢癌患者生存率降低相关。在此,我们对17例上皮性卵巢癌患者外周血和恶性腹水中的CD4(+) T细胞、CD8(+) T细胞和Treg亚群进行了详细表征。通过多色流式细胞术评估细胞分布、活化状态和增殖状态。与外周血相比,腹水中观察到CD8(+) 细胞毒性T细胞和Tregs显著积聚。此外,腹水中所有T细胞亚群均呈现向CD45RA(-) 效应/记忆亚群的偏移,在Treg群体中最为明显。与同一患者的血液来源细胞相比,恶性腹水中的调节性T细胞更具活化性且增殖率更高,腹水中其数量与积液中上皮细胞数量呈正相关。总之,我们证明了卵巢癌癌微环境中活化的CD4(+)、CD8(+) 和调节性T细胞的积聚。